RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma

Inclusion Criteria: * Aged ≥18 years (inclusive), male or female; * Patients with histologically or cytologically confirmed locally advanced or metastatic melanoma; * Prior genetic testing results showing positive NRAS mutation; * Patients who have failed prior anti-PD-1/PD-L1 therapy; * Able to take oral medications; * Voluntarily participate and sign the informed consent form, expected to have good compliance, and able to cooperate with the study according to the protocol requirements. Exclusion Criteria: * Currently participating in other clinical trials of drugs; * Patients who are pregnant or breastfeeding; * Other conditions deemed unsuitable for targeted therapy after multidisciplinary discussion; * Other conditions considered inappropriate for inclusion by the investigator, such as familial or social factors that may affect the safety of the subject or the collection of data.